Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice
Authors:
Lauren Wilson1; Zhenxiang Zhao1; Victoria Divino1; Matthew Bassan1; Briain O Hartaigh1; Kerem Ozer1
Affiliations
View DetailsHide Details
{{ getPageNum(PDFPage) }}
Share
Copy link
{{pageUrl}}
Keywords
Obesity
Congress oral presentation
GLP-1 RA
Semaglutide
RWE HEOR
Get notified when materials for ESC 2025 and future congresses become available:
Slide decks
Posters
Videos ... and more.
Get notified when materials for ESC 2025 and future congresses become available:
Slide decks
Posters
Videos ... and more.
{{ error.$message }}
Success
We will notify you when new materials become available for ESC 2025 and future congresses.
We will keep you updated in your inbox:
Subscribe to receive updates on related congresses in the same disease area: